Sangeeta Pankaj
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sangeeta Pankaj has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Vijayanand Choudhary
Gynecological Oncology, SCI Indira Gandhi Institute of Medical Sciences Patna, Bihar, India
22 shared publicationsSyed Nazneen
Gynecological Oncology, RCC, Indira Gandhi Institute of Medical Sciences (IGIMS), Patna, Bihar 800014 India
18 shared publicationsAnjili Kumari
Gynecological Oncology, RCC, Indira Gandhi Institute of Medical Sciences (IGIMS), Patna, Bihar 800014 India
17 shared publicationsJaya Kumari
Obstetrics and Gynecology, IGIMS, Patna, India
13 shared publicationsKavya Abhilashi
Gynecological Oncology, SCI Indira Gandhi Institute of Medical Sciences Patna, Bihar, India
11 shared publicationsAnita Kumari
Gynecological Oncology, RCC, Indira Gandhi Institute of Medical Sciences (IGIMS), Patna, Bihar 800014 India
8 shared publications
Latest Publications
- 5 November 2026
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 24 (4) , 115
Non Gestational Choriocarcinoma Germ Cell Tumor of Ovary:- A Rare Case Report
- 5 November 2026
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 24 (4) , 115
Non Gestational Choriocarcinoma Germ Cell Tumor of Ovary:- A Rare Case Report
- 14 October 2026
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 24 (4) , 79
TTF-1 Positive Primary a Small Cell Neuroendocrine Carcinoma of Cervix an Unusal Diagnosis
- 14 October 2026
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 24 (4) , 79
TTF-1 Positive Primary a Small Cell Neuroendocrine Carcinoma of Cervix an Unusal Diagnosis
- 27 December 2025
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 24 (1) , 15
A Study on Knowledge Attitude and Practise of Cervical Cancer Screening and its Prevention by HPV Vaccination among Medical College Students
- 27 December 2025
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 24 (1) , 15
A Study on Knowledge Attitude and Practise of Cervical Cancer Screening and its Prevention by HPV Vaccination among Medical College Students
- 27 November 2025
- Published by Springer Nature in The Journal of Obstetrics and Gynecology of India
- p. 1-3
Pigmentary Demarcation Line-Rare Presentation During Pregnancy: Case Report
- 27 November 2025
- Published by Springer Nature in The Journal of Obstetrics and Gynecology of India
- p. 1-3
Pigmentary Demarcation Line-Rare Presentation During Pregnancy: Case Report
- 5 September 2025
- Published by Springer Nature in The Journal of Obstetrics and Gynecology of India
- p. 1-3
Primary Ovarian Diffuse Large B Cell Lymphoma: A Diagnostic Challenge
- 5 September 2025
- Published by Springer Nature in The Journal of Obstetrics and Gynecology of India
- p. 1-3
Primary Ovarian Diffuse Large B Cell Lymphoma: A Diagnostic Challenge
- 3 December 2024
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 23 (1) , 1-4
Cellular Angiofibroma of Vagina: A Rare Tumor with Unique Pathology
- 3 December 2024
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 23 (1) , 1-4
Cellular Angiofibroma of Vagina: A Rare Tumor with Unique Pathology
- Open Access
- 14 July 2024
- Published by African Journals Online (AJOL) in Malawi Medical Journal
- Vol. 36 (2) , 120-127
Efficacy of HPV E6/E7 mRNA assay, HPV DNA test and cytology in detection of high grade cervical lesions and invasive cancer at a tertiary care center in India
BackgroundCervical cancer is caused by human papillomavirus (HPV) and remains a major public health issue. There are several methods for its diagnosis. Knowing their comparative usefulness may help in devising an appropriate strategy for early detection of this gynecological cancer in resource-constrained setting. AimThis study aims to evaluate the efficacy of human papillomavirus (HPV) E6/E7 mRNA assay, HPV DNA test and cytology in detection of high grade cervical lesions and invasive cervical carcinoma at a tertiary care center in India.MethodsA total of 106 women were recruited in this hospital based study and underwent molecular tests (HPV DNA test and mRNA assay), cytological test and colposcopic-guided biopsy. Histopathological diagnosis was considered as the gold standard. ResultsWe observed that 56 out of 106 participants had abnormal results in the terms of positive HPV DNA or E6/E7 mRNA with or without abnormal cytology or had histopathologically confirmed pre-malignant/malignant lesion. 47.2% (50/106) and 32% (34/106) women were positive for HPV DNA and E6/E7 mRNA respectively. 33% (35/106) women had abnormal cytology and 29.2% (31/106) had histologically confirmed CIN II and higher lesions. Sensitivity and specificity of cytology and HPV DNA for CIN III+ lesions were calculated as 92%, 90.4% versus 88% & 68% respectively. mRNA assay was found to be more sensitive (96%) and specific (93.3%) than other tests in detecting CIN II + lesions. ConclusionE6/E7 mRNA assay seems superior to HPV DNA test and cytology in detection of high grade cervical lesions and invasive carcinoma. It may be used as an alternative or adjunct to HPV DNA test or cytology for the purpose of cervical cancer screening and also be helpful in reducing the load for colposcopy.
- 14 July 2024
- Published by African Journals Online (AJOL) in Malawi Medical Journal
- Vol. 36 (2) , 120-127
Open AccessEfficacy of HPV E6/E7 mRNA assay, HPV DNA test and cytology in detection of high grade cervical lesions and invasive cancer at a tertiary care center in India
BackgroundCervical cancer is caused by human papillomavirus (HPV) and remains a major public health issue. There are several methods for its diagnosis. Knowing their comparative usefulness may help in devising an appropriate strategy for early detection of this gynecological cancer in resource-constrained setting. AimThis study aims to evaluate the efficacy of human papillomavirus (HPV) E6/E7 mRNA assay, HPV DNA test and cytology in detection of high grade cervical lesions and invasive cervical carcinoma at a tertiary care center in India.MethodsA total of 106 women were recruited in this hospital based study and underwent molecular tests (HPV DNA test and mRNA assay), cytological test and colposcopic-guided biopsy. Histopathological diagnosis was considered as the gold standard. ResultsWe observed that 56 out of 106 participants had abnormal results in the terms of positive HPV DNA or E6/E7 mRNA with or without abnormal cytology or had histopathologically confirmed pre-malignant/malignant lesion. 47.2% (50/106) and 32% (34/106) women were positive for HPV DNA and E6/E7 mRNA respectively. 33% (35/106) women had abnormal cytology and 29.2% (31/106) had histologically confirmed CIN II and higher lesions. Sensitivity and specificity of cytology and HPV DNA for CIN III+ lesions were calculated as 92%, 90.4% versus 88% & 68% respectively. mRNA assay was found to be more sensitive (96%) and specific (93.3%) than other tests in detecting CIN II + lesions. ConclusionE6/E7 mRNA assay seems superior to HPV DNA test and cytology in detection of high grade cervical lesions and invasive carcinoma. It may be used as an alternative or adjunct to HPV DNA test or cytology for the purpose of cervical cancer screening and also be helpful in reducing the load for colposcopy.
- 3 May 2024
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 22 (2) , 1-5
HE-4 A Novel Tumour Marker for Ovarian Mass and Its Comparison with CA 125
- 3 May 2024
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 22 (2) , 1-5
HE-4 A Novel Tumour Marker for Ovarian Mass and Its Comparison with CA 125
- 15 February 2024
- Published by Springer Nature in The Journal of Obstetrics and Gynecology of India
- Vol. 74 (5) , 418-423
Predictive Role of HE4 in Diagnosis of Ovarian Tumors
Background Approximately 20% of women develop an ovarian cyst or pelvic mass at some point in their lives. Due to high false positivity of CA-125, women with various benign ovarian tumors simulating malignant masses undergo extensive debulking surgery resulting in increased morbidity. Serum HE4 is a useful test for better discrimination of benign or malignant nature of pelvic masses in preoperative period. Our study gives an update on the biological markers specifically CA-125 and a novel tumor marker HE4 and aims to reduce the debulking surgeries done for benign pathology. Materials and Methods The total study population (n = 302) included women who were operated with suspicious ovarian malignant mass (n = 238) with benign (n = 98), borderline (n = 6), and malignant (n = 134) ovarian tumors. Cutoff of CA-125 was 35 U/mL, and for HE4 140 pM for postmenopausal and 70 pM for premenopausal women were calculated at 86% and 81% accuracy, respectively. Statistical analysis was done using SPSS version 20. Results The cutoff values of CA-125 were able to differentiate between benign, borderline, and malignant tumors with statistical significance (p < 0.05), whereas the cutoff values of HE4 significantly (p < 0.05) differentiated benign tumors from the malignant tumors, but not from the borderline tumors. Serum CA-125 has significantly higher sensitivity and NPV (95%, 72%, respectively) compared to HE4 (81%, 52%) and combined HE4 plus CA-125 (84%, 59%), whereas specificity, PPV, and AUC were higher for combined CA-125 plus HE4 (93%, 98%, 90%, respectively) compared to HE4 (83%, 95%, 88%) and CA-125 (48%, 88%, 87%). Conclusion Measuring serum HE4 along with CA-125 in preoperative diagnosis helps in excluding benign ovarian tumors in which CA-125 was falsely raised, especially in center where frozen section is not available, thus potentially decreasing morbid debulking surgeries done for benign ovarian tumors.
- 15 February 2024
- Published by Springer Nature in The Journal of Obstetrics and Gynecology of India
- Vol. 74 (5) , 418-423
Predictive Role of HE4 in Diagnosis of Ovarian Tumors
Background Approximately 20% of women develop an ovarian cyst or pelvic mass at some point in their lives. Due to high false positivity of CA-125, women with various benign ovarian tumors simulating malignant masses undergo extensive debulking surgery resulting in increased morbidity. Serum HE4 is a useful test for better discrimination of benign or malignant nature of pelvic masses in preoperative period. Our study gives an update on the biological markers specifically CA-125 and a novel tumor marker HE4 and aims to reduce the debulking surgeries done for benign pathology. Materials and Methods The total study population (n = 302) included women who were operated with suspicious ovarian malignant mass (n = 238) with benign (n = 98), borderline (n = 6), and malignant (n = 134) ovarian tumors. Cutoff of CA-125 was 35 U/mL, and for HE4 140 pM for postmenopausal and 70 pM for premenopausal women were calculated at 86% and 81% accuracy, respectively. Statistical analysis was done using SPSS version 20. Results The cutoff values of CA-125 were able to differentiate between benign, borderline, and malignant tumors with statistical significance (p < 0.05), whereas the cutoff values of HE4 significantly (p < 0.05) differentiated benign tumors from the malignant tumors, but not from the borderline tumors. Serum CA-125 has significantly higher sensitivity and NPV (95%, 72%, respectively) compared to HE4 (81%, 52%) and combined HE4 plus CA-125 (84%, 59%), whereas specificity, PPV, and AUC were higher for combined CA-125 plus HE4 (93%, 98%, 90%, respectively) compared to HE4 (83%, 95%, 88%) and CA-125 (48%, 88%, 87%). Conclusion Measuring serum HE4 along with CA-125 in preoperative diagnosis helps in excluding benign ovarian tumors in which CA-125 was falsely raised, especially in center where frozen section is not available, thus potentially decreasing morbid debulking surgeries done for benign ovarian tumors.